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Background: Limited resection and stereotactic body radiotherapy 
(SBRT) have emerged as treatment options for older patients with 
early-stage non–small-cell lung cancer (NSCLC), who are not good 
candidates for lobectomy.
Methods: We used the Surveillance, Epidemiology and End Results-
Medicare registry to identify patients older than 65 years with stage 
I to II NSCLC and negative lymph nodes treated with SBRT ver-
sus limited resection. We fitted a propensity score model predicting 
the use of SBRT and compared adjusted overall survival of patients 
treated with SBRT versus limited resection. Secondary analyses 
stratified the sample by type of limited resection (wedge versus seg-
mentectomy), age (≤75 versus >75 years), and tumor size (<3 versus 
≥3 cm). We also compared rates of surgical complications and SBRT-
related toxicity in the two groups.
Results: We identified 2243 patients of which 362 (16%) patients 
received SBRT. SBRT-treated patients were older, had higher comor-
bidity scores, and had larger tumors (p < 0.001 for all comparisons). 
Adjusted analyses showed no differences in survival (hazard ratio [HR], 
1.19; 95% confidence interval [CI], 0.97–1.47) among patients treated 
with SBRT versus limited resection. Although survival of patients who 
underwent SBRT versus wedge resection was not different (HR, 1.22; 
95% CI, 0.98–1.52), SBRT was associated with worse outcomes when 
compared with segmentectomy (HR, 1.55; 95% CI, 1.18–2.03). Adverse 
events were most often respiratory and more frequent in the patients 
treated with limited resection (28% versus 14%, p < 0.001).
Conclusion: SBRT is better tolerated and associated with similar 
survival when compared with wedge resection but not with segmen-
tectomy in older patients with node-negative NSCLC.
Key Words: Non–small-cell lung cancer, Radiotherapy, Wedge 
resection, Segmentectomy, Radiosurgery.
(J Thorac Oncol. 2015;10: 1201–1206)
The prevalence of early-stage non–small-cell lung cancer (NSCLC) is expected to increase given the current trends 
in population aging and the widespread implementation of 
computed tomography (CT) screening.1 Although standard 
curative treatment for lung cancer is lobectomy, full resection 
is often precluded in older patients by multiple comorbidities, 
frailty, high operative risk, and/or borderline lung function. 
These patients are frequently offered less aggressive but still 
effective approaches such as limited resection (segmentec-
tomy or wedge resection) and, more recently, stereotactic body 
radiotherapy (SBRT). SBRT delivers targeted radiation to the 
tumor in doses varying from 30 to 54 Gy divided in one to five 
fractions.2 Compared with standard radiotherapy (RT), SBRT 
uses a higher dose per fraction and delivers the treatment by 
means of multiple beams providing higher radiation doses to 
the tumor while minimizing normal tissue exposure.
In single-arm phase I/II trials of inoperable patients,3–5 
SBRT has been shown to provide 3-year survival rates of 56% 
to 60%. However, two phase III studies comparing SBRT 
with lobectomy and one phase III study comparing SBRT 
with sublobar resection in potentially operable patients have 
been closed because of slow patient accrual.6,7 Similarly, 
there is limited information regarding SBRT-related toxici-
ties, particularly among few selected older individuals treated 
in the community. Despite the lack of comparative data, use 
of SBRT for early-stage lung cancer is rapidly increasing. In 
this study, we used population-based cancer data to compare 
survival and toxicity of SBRT versus limited resection among 
older patients with node-negative stage I to II NSCLC.
PATIENTS AND METHODS
This study used data from the Surveillance, 
Epidemiology, and End Results (SEER)-Medicare registry. 
Cancer information in the linked database originates from 
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17 regional registries that combined represent approximately 
26% of the U.S. population.8 The study cohort consisted of 
patients with histologically confirmed, primary NSCLC diag-
nosed between 2002 and 2009 that underwent limited resec-
tion (wedge or segmentectomy) or SBRT. The study was 
limited to NSCLCs less than or equal to 5 cm in size without 
nodal involvement (N0) or distant metastases. Patients who 
received preoperative chemotherapy or RT and who under-
went conventional RT were excluded. Patients receiving hos-
pice care or residing in a nursing home were excluded because 
they are not usually candidates for curative treatments. To cap-
ture data regarding treatment and comorbidities, patients had 
both parts A (inpatient) and B (outpatient) Medicare coverage 
within 1 year of diagnosis. We excluded patients enrolled in 
health maintenance organizations, because Medicare does not 
collect claims on these individuals.
We obtained patient sociodemographic information 
from SEER-Medicare. The burden of coexisting illnesses was 
calculated for each patient based on the Deyo adaptation of 
Charlson’s comorbidity index using inpatient, outpatient, and 
physician Medicare claim files.9 We used information from 
Hospice and Home Health Agency files to identify the use of 
home health services, and we used these as a proxy for poor 
functional status.10
Histological subtype was coded using International 
Classification of Disease for Oncology, 3rd edition based 
on the data extracted from SEER. Cancer stage was clas-
sified according to the 7th edition of the American Joint 
Committee on Cancer Criteria based on detailed tumor 
extension, size, lymph node involvement, and systemic 
dissemination information reported by SEER.11 The 
extent of pretreatment staging was determined based on 
the claims indicating the use of bone scan, positron emis-
sion tomography (PET), endobronchial ultrasound-guided 
transbronchial lymph node aspiration (EBUS), esopha-
geal ultrasound-guided lymph node aspiration (EUS), and 
mediastinoscopy.
Surgical treatment within 6 months of diagnosis was 
ascertained from SEER and Medicare surgical codes.12 Receipt 
of SBRT within the same timeframe was ascertained using the 
Healthcare Common Procedure Coding System code 77435; 
current procedural terminology-4 codes 77373, G0173, 
G0251, G0339, G0340, 61793, and 0082T; and International 
Classification of Diseases-9 procedure codes 92.3 and 92.30 
to 92.39.13
Overall and lung cancer–specific survivals were calcu-
lated from the date of treatment initiation to the date of death 
reported in Medicare and SEER, respectively. For analyses of 
lung cancer–specific survival, deaths from other causes were 
classified as censored. The cause of death was obtained from 
death certificate data provided by SEER.
Surgical adverse events were defined as the presence 
of cardiovascular complications, thromboembolic events, 
respiratory complications, transfusions, and extrapulmonary 
infections based on the inpatient and outpatient claims within 
90 days of treatment.14,15 Similarly, we identified potentially 
radiation-related adverse events using inpatient and outpatient 
claims for esophagitis, radiation pneumonitis, and hemoptysis 
within the same timeframe.
Statistical Analysis
Characteristics of patients treated with SBRT versus 
limited resection were compared using the chi-square test or 
t test. Because patient and tumor characteristics were likely 
related to the decision of using SBRT versus limited resection, 
we used propensity score methods to control for allocation 
bias. The probability of undergoing SBRT was estimated using 
logistic regression including patient characteristics (sociode-
mographics, comorbidity index, and use of home services), 
tumor information (size, extension, location, and histology), 
use of preoperative tests, time from diagnosis to treatment 
initiation, and year of diagnosis. Then we used Cox regres-
sion to compare survival of patients treated with SBRT versus 
limited resection. Four different and complementary methods 
were used to perform these analyses. First, we included the 
propensity score as a continuous covariate in the Cox model. 
Second, we divided patients into quintiles based on propensity 
scores and compared survival using a stratified Cox model. 
Third, we used inverse probability weighting in the cox model 
after deleting observations with extreme weights. Finally, we 
matched patients based on their propensity scores using a 
greedy algorithm and compared survival using a Cox model 
for correlated data. We also conducted secondary analyses 
stratifying the sample according to age (≤75 or >75 years), 
type of surgery (segmentectomy or wedge resection), and 
tumor size (<3 cm versus ≥3 cm).
Patients receiving wedge resection or segmentec-
tomy usually undergo pathological lymph node evaluation. 
Conversely, most SBRT-treated patients are staged clinically 
and, therefore, may be more likely to have undetected N1 
disease, a risk factor for worse survival. To assess potential 
impact of differential staging, we performed secondary analy-
ses limiting the cohort to patients receiving SBRT who under-
went more comprehensive mediastinal staging (i.e., PET, 
EBUS, EUS, or mediastinoscopy). In addition, we performed 
a sensitivity analysis to assess whether different rates of unde-
tected N1 disease in SBRT-treated patients versus those who 
underwent surgery could explain survival differences between 
the two groups. Toxicity rates were estimated among patients 
receiving SBRT versus limited resection and compared using 
a logistic regression model adjusted for propensity scores.
On the basis of the expected number of patients treated 
with SBRT versus limited resection and assumed number of 
deaths in the cohort, we estimated that the study will have 
more than 80% power to detect an increased hazard of death 
among SBRT-treated patients of 1.25 at a 0.05 significance 
level. Analyses were done with SAS software (version 9.3; 
SAS Institute Inc., Cary, NC) using two tailed p values. The 
study was exempted by the institutional review board.
RESULTS
We identified 2243 patients older than 65 years with 
confirmed node-negative stage I or II NSCLC less than or 
equal to 5 cm in size. Of these, 362 (16%) patients received 
SBRT. Baseline patient characteristics are summarized in 
Table 1. Patients who received SBRT were older, more likely 
to be woman, unmarried, had higher comorbidity scores, 
and had larger tumors (p < 0.001 for all comparisons). PET 
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use was similar among patients in the two treatment groups 
(p = 0.45). Although a larger number of patients treated 
with limited resection underwent a staging mediastinoscopy 
(p < 0.001), few patients (<3%) in either group had EBUS 
or EUS. Among the patients receiving limited resection, 1337 
(71%) patients underwent wedge resection and 544 (29%) 
patients had a segmentectomy. After adjusting for propensity 
scores, the distribution of baseline characteristics was similar 
in both groups (Table 1).
Cox regression showed no significant differences in 
overall (hazard ratio [HR], 1.19, 95% confidence interval 
[CI], 0.97–1.47) or lung cancer–specific (HR, 1.46; 95% CI, 
0.97–2.19) survival among patients treated with SBRT ver-
sus limited resection, after adjustment for propensity scores. 
Stratified analysis by propensity score quintiles also showed 
no significant differences in overall survival (HR, 1.20; 95% 
CI, 1.00–1.45) among groups but worse lung cancer–specific 
survival (HR, 1.45; 95% CI, 1.01–2.10) in SBRT-treated 
patients. By using inverse probability weighting, we found 
that both overall (HR, 1.00; 95% CI, 0.85–1.18) and lung 
cancer–specific (HR, 1.36; 95% CI, 0.98–1.89) survivals were 
not significantly different in both treatment arms. Finally, pro-
pensity score matching also showed similar results for overall 
survival (HR, 1.20; 95% CI, 0.98–1.49) and lung cancer–
specific survival (HR, 1.48; 95% CI, 0.97–2.42; Table 2). 
Findings remained consistent in secondary analyses stratify-
ing patients by age (>75 or ≤75 years) and tumor size (>3 or 
≤3 cm; Table 2).
When analyses were stratified by type of surgery, SBRT-
treated patients had significantly worse overall survival (HR, 
1.55; 95% CI, 1.18–2.03) and lung cancer–specific survival 
(HR, 1.80; 95% CI, 1.09–2.97) compared with patients treated 
with segmentectomy. However, overall (HR, 1.22, 95% CI, 
0.98–1.52) and lung cancer–specific (HR, 1.45; 95% CI, 
0.95–2.21) survivals after wedge resection and SBRT were 
not significantly different.
Analyses restricted to patients receiving SBRT who 
underwent mediastinal lymph node staging showed no signifi-
cant differences in overall survival (HR, 1.17; 95% CI, 0.91–
1.49) or lung cancer–specific (HR, 1.52; 95% CI, 0.93–2.47) 
TABLE 1.  Characteristics of Study Patients Treated with Limited Resection vs. Stereotactic Body Radiotherapy
Characteristic Limited Resection (n = 1881) SBRT (n = 362) p Value Adjusteda p Value
Age (yr), mean (SD) 76 (5.7) 78 (6.5) <0.001 0.99
Female, n (%) 1072 (57) 235 (65) 0.01 0.99
Married, n (%) 994 (53) 156 (43) <0.001 0.99
Race/ethnicity, n (%) 0.01 0.99
  White 1679 (89) 313 (86)
  Black 99 (5) 29 (8)
  Hispanic 38 (2) >11 (>3)b
  Other 65 (4) ≤11 (≤3)
Median income, n (%) 0.09 0.99
  First quartile 405 (22) 94 (26)
  Second quartile 444 (24) 90 (25)
  Third quartile 480 (25) 92 (25)
  Fourth quartile 551 (29) 85 (23)
Comorbidity score, n (%) <0.001 0.99
  ≤1.0 591 (31) 67 (18)
  1.0–2.0 582 (31) 121 (33)
  >2.0 708 (38) 174 (48)
Histology, n (%) <0.001 0.99
  Adenocarcinoma 1075 (57) 208 (57)
  Squamous cell 595 (32) 136 (38)
  Large cell 52 (3) >11 (>3)
  Other 159 (8) ≤11 (≤3)
Size (cm), n (%) <0.001 0.99
  ≤2.0 1091 (58) 137 (38)
  2.1–3.0 530 (28) 144 (40)
  3.1–5.0 260 (14) 81 (22)
PET scan, n (%) 822 (44) 166 (46) 0.45 0.99
Bone scan, n (%) 220 (12) 33 (9) 0.16 0.99
Mediastinoscopy, n (%) 218 (12) ≤11 (≤3) <0.001 0.93
aAdjusted for propensity scores.
bExact number of patients not reported in cells with ≤11 individuals to maintain patients confidentiality.
PET, positron emission tomography.
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survival when SBRT was compared with limited resection. 
Because patients receiving SBRT are less likely to have inva-
sive staging compared with the patients treated by limited 
resection, we performed a sensitivity analysis to explore the 
effect on survival of differential misclassification of N1 nodal 
status in the two groups. Survival after SBRT approached that 
of limited resection because the assumed proportion of N1 
cases among clinically staged SBRT-treated patients increased 
(Table 3). However, SBRT was not superior to limited resec-
tion in any of the plausible scenarios explored.
Respiratory complications within 3 months of treat-
ment occurred most often in those treated with surgery (28%) 
compared with those treated with SBRT (14%; p < 0.0001; 
Table 4). Cardiovascular events occurred in 3% of patients 
treated with surgery; however, this complication was rare 
(<1%) after SBRT. SBRT was relatively well tolerated with 
less than 3% of patients developing radiation pneumonitis, 
and no patients were treated for hemoptysis or radiation-
induced esophagitis.
DISCUSSION
The incidence of early-stage lung cancer is expected to 
considerably increase with the widespread implementation 
of low-dose CT screening.1 As a result, clinicians will more 
frequently be faced with difficult treatment decisions, particu-
larly for older smokers some of whom may have borderline 
lung function or comorbidities. Less invasive procedures such 
as SBRT and limited resection provide attractive treatment 
options for older patients because of their lower rates of peri-
operative morbidity. However, these procedures lead to higher 
rates of long-term cancer recurrence compared with lobec-
tomy, a problem that may be less significant in older patients 
who may have a limited life expectancy. By using population-
based cancer data, we showed that SBRT and wedge resection 
are associated with similar long-term survival, whereas seg-
mentectomy performs better than SBRT. Moreover, SBRT was 
relatively well tolerated and associated with low rates of severe 
toxicity. Our findings provide further evidence regarding the 
potential role of SBRT in the treatment of older patients with 
early-stage lung cancer.
Both potentially operable16 and inoperable3–5,17 patients 
with early-stage NSCLC have been treated with SBRT in 
small5,16 studies that have shown comparable survival rates 
compared with historical controls treated with limited resection. 
Outcomes after SBRT are in general better than those observed 
TABLE 2.  Comparison of Survival of Older Patients Treated with Limited Resection vs. Stereotactic Body Radiotherapy
Propensity Score Model n Overall Survival, HR (95% CI)
Lung Cancer–Specific Survival,  
HR (95% CI)
Primary analyses
  Adjusted 2243 1.19 (0.97–1.47) 1.46 (0.97–2.19)
  Stratified 2243 1.20 (1.00–1.45) 1.45 (1.01–2.10)
  Matched 972 1.20 (0.98–1.49) 1.48 (0.97–2.42)
  Inverse probability weighted 2240a 1.00 (0.85–1.18) 1.36 (0.98–1.89)
Secondary analyses
  Age ≤ 75 yr 1066 1.11 (0.77–1.61) 1.44 (0.70–2.97)
  Age > 75 yr 1177 1.24 (0.95–1.60) 1.49 (0.91–2.42)
  Size ≤ 3 cm 1902 1.21 (0.95–1.53) 1.38 (0.65–2.96)
  Size > 3 cm 341 1.18 (0.75–1.86) 1.62 (1.01–2.61)
  Wedge resection vs. SBRT 1699 1.22 (0.98–1.52) 1.45 (0.95–2.21)
  Segmentectomy vs. SBRT 906 1.55 (1.18–2.03) 1.80 (1.09–2.97)
  Limited resection vs. SBRT with lymph 
 node evaluationb
2059 1.17 (0.91–1.49) 1.52 (0.93–2.47)
aObservations with extreme weights were deleted.
bLymph node evaluation included pretreatment endobronchial ultrasound-guided lymph node biopsy, endoscopic ultrasound-guided lymph node biopsy, mediastinoscopy, or PET 
scan in the patients treated with SBRT.
CI, confidence interval; HR, hazard ratio; PET, positron emission tomography; SBRT, stereotactic body radiotherapy.
TABLE 3.  Sensitivity Analyses Modeling the Impact of 
Increased N1 Disease in SBRT-Treated Patients
Probability of N1 Disease (%)
Increased  
Hazard  
of Death with  
N1 Disease
Adjusted Hazard 






20 10 1.3 1.14 (0.94–1.15)
20 10 1.5 1.12 (0.92–1.37)
20 10 2.0 1.07 (0.88–1.31)
30 10 1.3 1.11 (0.91–1.35)
30 10 1.5 1.07 (0.88–1.31)
30 10 2.0 0.99 (0.81–1.21)
40 10 1.3 1.08 (0.88–1.32)
40 10 1.5 1.02 (0.84–1.25)
40 10 2.0 0.92 (0.75–1.12)
50 10 1.3 1.05 (0.86–1.28)
50 10 1.5 0.99 (0.81–1.2)
50 10 2.0 0.86 (0.74–1.05)
aProbability of N1 disease was held constant for patients treated with limited 
resection because these patients are pathologically staged during surgery.
CI, confidence interval; SBRT, stereotactic body radiotherapy.
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among unresected stage I patients treated with conventional RT 
providing improved18,19 or similar survival and less toxicity.20 
After these promising initial results, phase III randomized trials 
comparing SBRT with lobectomy or limited resection were ini-
tiated by large oncological groups. However, two studies were 
terminated early because of poor accrual,6,7 and only one phase 
III study is ongoing but no longer recruiting patients.21,22
Other investigators have assessed the potential benefits 
of SBRT using observational data from single-institutional 
series.23–25 Population studies found improved survival among 
inoperable patients with early-stage lung cancer diagnosed in 
consecutive periods.26,27 As improvements in survival coin-
cided with the introduction of SBRT, the investigators attrib-
uted these findings to an uptake of this technique. However, 
these studies were greatly limited by a lack of patient level 
treatment data. Shirvani et al.28 used a prior release of the 
SEER database (including cases diagnosed during or before 
2007) to compare survival in patients receiving lobectomy, 
limited resection, conventional RT, and SBRT. The study, 
which included a relatively small number (n = 124) of SBRT 
cases, showed similar outcomes after limited resection ver-
sus SBRT. However, this study had limited long-term follow-
up information (because SBRT uptake mostly occurred after 
2007), did not report toxicity data, and was limited to early 
SBRT adopters, a factor that may limit the representative-
ness of their findings. An update of the study showed SBRT 
was inferior to lobectomy, but they did not directly compare 
SBRT with limited resection nor did they provide information 
on the effect of wedge resection or segmentectomy individu-
ally.29 In this study, we evaluated SBRT in a larger cohort of 
older patients and assessed long-term survival outcomes. The 
median follow-up was 38 months in the patients treated with 
limited resection and 27 months in the patients treated with 
SBRT. The longest follow-up time in the study was 9 years in 
either arm. This limits our ability to extrapolate results over 
a longer time horizon. In addition, we evaluated the impact 
of differential nodal evaluation. Staging of patients receiving 
SBRT relies heavily on imaging, which can be inaccurate and 
underestimate the extent of mediastinal nodal involvement. 
Sensitivity for identification of mediastinal lymph node 
involvement in lung cancer is 55% for CT scan and 77% for 
PET.30 Differential understaging (patients with N1 disease 
being classified as N0) may lead to an apparent worse survival 
among SBRT-treated patients. We addressed this potential bias 
by performing stratified and sensitivity analyses, which con-
firmed that limited resection and SBRT are associated with 
similar long-term outcomes despite potential misclassification 
of lymph node status in the SBRT-treated arm.
We also assessed the effectiveness of SBRT versus seg-
mentecomy or wedge resection separately. Segmentectomy is 
considered superior oncologically than wedge resection because 
it provides a larger parenchymal margin and an increased nodal 
yield.31,32 Previous data have shown that lobectomy and segmen-
tectomy for small clinical stage I NSCLC are equivalent, whereas 
wedge resection showed inferior outcomes.33–35 Consistent with 
these findings, our results suggest that segmentectomy should be 
preferred over SBRT even among older individuals.
Toxicity is particularly important when considering 
cancer treatment options with similar long-term survival. We 
used inpatient and outpatient claims data within 3 months 
of treatment to capture the rates of SBRT-related toxicity. 
Respiratory complications were common in both groups, 
likely reflecting a high prevalence of underlying lung disease. 
However, SBRT was associated with lower rates of respiratory 
and cardiovascular complications. There were very few (<3%) 
reported cases of radiation pneumonitis post-SBRT, and none 
required admission. However, it is possible that some SBRT-
treated patients had milder adverse events not captured by 
our claims-based criteria. Despite our limitations, our data 
strongly suggest that SBRT is relatively well tolerated and 
infrequently associated with hospital admissions. Thus, future 
studies should compare quality of life and explore the cost-
effectiveness of SBRT versus limited resection.
Comparative effectiveness studies are often limited 
by allocation bias because of systematic differences in the 
characteristics of patients treated with SBRT versus limited 
resection. These differences may become confounders of the 
effect of type of therapy. In this study, we used propensity 
score methods to balance the distribution of measured prog-
nostic factors across study arms. Moreover, we limited the 
cohort to patients who could have been candidates for either 
treatment and had detailed tumor information. However, we 
could not control for unmeasured covariates. Thus, the level 
of evidence provided by our study does not match with those 
obtained from randomized controlled trials. However, no 
data about the comparative effectiveness of SBRT are avail-
able from prospective trials, because these were prematurely 
terminated. Thus, our and previous observational studies 
provide the best available information regarding the poten-
tial role of SBRT. In addition, the large numbers of elderly 
patients in the registry allowed for appropriately powered 
comparisons among specific treatments. This is of particu-
lar advantage for the analysis of outcomes such as adverse 
events, which have low frequency. Another advantage is that 
survival and toxicity rates reported in our study represent 
those expected among patients encountered in routine care.
Currently, more than half of American radiation oncolo-
gists offer SBRT; use of this technique has considerably increased 
TABLE 4.  Adverse Events after Treatment
Type of Toxicity, n (%)
Limited  
Resection (n = 1881)
SBRT  
(n = 362) p Valuea
Transfusion 32 (1) — —
Reoperation 15 (1) — —
Extrapulmonary 
complications
201 (9) 21 (1) <0.001
Cardiovascular 
complications
75 (3) <11 (<3) 0.21
Thromboembolic 
complications
117 (5) 25 (7) 0.37
Respiratory 
complications
621 (28) 50 (14) <0.001
Hemoptysis — 0 —
Radiation pneumonitis — <11 (<3) —
aAdjusted for propensity scores.
SBRT, stereotactic body radiotherapy.
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in the last 5 years.36 We found that SBRT is better tolerated and 
associated with similar survival when compared with wedge 
resection but not with segmentectomy in older patients with 
node-negative NSCLC. Our results allow for a better assessment 
of the potential benefits and risks of SBRT versus limited resec-
tion in older patients who are not candidates for lobectomy.
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